Tag: ASX: IMM
First dose administered in Efti, BAVENCIO trial for metastatic urothelial cancer
Immutep Limited, a pioneering clinical-stage biotechnology company specializing in LAG-3 immunotherapies, announced the enrollment and safe dosing of the first patient in the INSIGHT-005 Phase I trial in the fight against metastatic urothelial carcinoma.
Immutep gets green light for large-scale cancer product manufacturing for clinical trials
Immutep Limited, a clinical-stage biotechnology company specialising in LAG-3 immunotherapies for cancer and autoimmune diseases, has received regulatory authorisation for the commercial manufacturing of Eftilagimod Alpha (efti) at a scale of 2,000 litres for clinical trial use.
Featured Article
How growth capital is helping an Australian manufacturer go global
There’s a particular kind of ingenuity that flourishes in regional Australia. Away from the noise of major business centres, founders build companies that quietly become world leaders in their field, solving deep specialised problems that global markets didn’t know could be solved. Modra Technology, based in Warragul in regional Victoria, is one of those companies.
